Online inquiry

IVTScrip™ mRNA-Anti-ITGAV&ITGB3, MEDI-522(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ11291MR)

This product GTTS-WQ11291MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets ITGAV&ITGB3 gene. The antibody can be applied in Sarcoma research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 0
Species Humanized
RefSeq NM_001144999.3; NM_000212.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 3685; 3690
UniProt ID P06756; P05106
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-ITGAV&ITGB3, MEDI-522(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ11291MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ8554MR IVTScrip™ mRNA-Anti-CD4, Hu5A8(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA Hu5A8
GTTS-WQ9851MR IVTScrip™ mRNA-Anti-CD37, K7153A(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA K7153A
GTTS-WQ7914MR IVTScrip™ mRNA-Anti-CSF2, GSK3196165(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA GSK3196165
GTTS-WQ14174MR IVTScrip™ mRNA-Anti-ANGPT2, REGN-910(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA REGN-910
GTTS-WQ9839MR IVTScrip™ mRNA-Anti-ICOS, JTX-2011(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA JTX-2011
GTTS-WQ13370MR IVTScrip™ mRNA-Anti-LRRC15, PR-1498487(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA PR-1498487
GTTS-WQ14817MR IVTScrip™ mRNA-Anti-CD70, SGN-70(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA SGN-70
GTTS-WQ4358MR IVTScrip™ mRNA-Anti-B7, BMS-188667(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA BMS-188667
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW